Question 1

What is Johnson & Johnson's P/E ratio?

Accepted Answer

Johnson & Johnson (JNJ) P/E ratio is 29.7× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Johnson & Johnson?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Johnson & Johnson specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is Johnson & Johnson's P/E ratio high or low?

Accepted Answer

Johnson & Johnson's P/E ratio of 29.7× is above its own 5-year average of 21.4× and above the sector median of 24.2×. That places the current reading at the 89th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Johnson & Johnson's historical P/E ratio range?

Accepted Answer

In the available daily series, Johnson & Johnson (JNJ) P/E ratio has ranged from a low of 9.1× in 2024 to a high of 288.6× in 2017. The 5-year average is 21.4× and the 5-year median is 22.8×.

Question 7

What was Johnson & Johnson's P/E ratio in 2025?

Accepted Answer

Johnson & Johnson (JNJ) P/E ratio at the end of 2025 was 18.8×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Johnson & Johnson's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$504B	$26.8B	18.8×	-5.7×	Dec 28, 2025
2024	$345B	$14.1B	24.5×	+13.8×	Dec 29, 2024
2023	$377B	$35.2B	10.7×	-15.0×	Dec 31, 2023
2022	$462B	$17.9B	25.7×	+4.2×	Dec 31, 2022
2021	$450B	$20.9B	21.5×	-6.6×	Dec 31, 2021
2020	$414B	$14.7B	28.2×	+2.8×	Dec 31, 2020
2019	$384B	$15.1B	25.4×	+2.4×	Dec 31, 2019
2018	$352B	$15.3B	23.0×	-265.6×	Dec 31, 2018
2017	$375B	$1.3B	288.6×	+269.7×	Dec 31, 2017
2016	$312B	$16.5B	18.9×	+0.5×	Dec 31, 2016
2015	$283B	$15.4B	18.4×	+0.5×	Dec 31, 2015
2014	$291B	$16.3B	17.8×	-0.8×	Dec 31, 2014
2013	$258B	$13.8B	18.7×	+0.7×	Dec 31, 2013
2012	$195B	$10.9B	17.9×	-0.6×	Dec 31, 2012
2011	$179B	$9.67B	18.5×	+5.8×	Dec 31, 2011
2010	$170B	$13.3B	12.7×	-1.8×	Dec 31, 2010
2009	$178B	$12.3B	14.5×	+1.7×	Dec 31, 2009
2008	$166B	$12.9B	12.8×	-5.2×	Dec 31, 2008
2007	$190B	$10.6B	18.0×	+0.6×	Dec 31, 2007
2006	$192B	$11.1B	17.4×	-0.3×	Dec 31, 2006
2005	$179B	$10.1B	17.7×	-4.4×	Dec 31, 2005
2004	$188B	$8.51B	22.1×	+0.8×	Dec 31, 2004
2003	$153B	$7.2B	21.3×	-2.9×	Dec 31, 2003
2002	$160B	$6.6B	24.2×	—	Dec 31, 2002


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Johnson & Johnson (JNJ) 2002-2026

P/E Ratio daily chart for Johnson & Johnson (JNJ)

Historical P/E Ratio for Johnson & Johnson (JNJ) from 2002 to 2025

About P/E Ratio at Johnson & Johnson (JNJ)

Johnson & Johnson P/E Ratio by Year

Johnson & Johnson P/E Ratio 2025: 18.8×

Johnson & Johnson P/E Ratio 2024: 24.5×

Johnson & Johnson P/E Ratio 2023: 10.7×

Johnson & Johnson P/E Ratio 2022: 25.7×

Johnson & Johnson P/E Ratio 2021: 21.5×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Johnson & Johnson (JNJ) Key Financials